Abstract:Developing biocompatible, multifunctional and in-situ labeling nanoplatform is high challenging for molecular imaging. Organic derivates melanin nanoparticles (MNPs) holds great potential to be multimodal contrast agents, and have been used for photoacoustic imaging, magnetic resonance imaging, and Cu-64 PET imaging with simple modifications. In order to extend MNPs application in molecular imaging, here a novel radio-nuclide was applied to in-situ labeling of MNPs. Large numbers of active dihydroxyindole/indolequinone groups and natural binding ability of MNPs enabled them to have the ability to label different types of radionuclides which have unique half-life and functions, especially long-life elemental nuclide. This project explored the in-situ labeling methods of organic melanin nanoparticles with a promising diagnostic radionuclides named Iodine-124 (I-124), and using this novel multifunctional organic nanoparticles for preliminary molecular imaging studies. Generally, ultrafine particle size melanin nanoparticles (5.5 nm in diameter) were prepared by ultrasonication method using naturally occurring melanin, then PEG(3500) which had amino group at both ends was used as a stabilizer agent to obtain PEG-MNP nanocarriers (7.5 nm in diameter) with better water solubility and stability. The nanoparticles were full characterized by dynamic light scattering (DLS), transmission electron microscope (TEM) and H-1 NMR, respectively. Then, one kind of elemental nuclide was labeled. Classic iodine labeled method with N-Bromo Succinimide (NBS) was used as oxidant to oxidize active dihydroxyindole/indolequinone ring of PEG-MNP for electrophilic substitution reaction labeling I-124 (100.8 h). This reaction rate is extremely fast (60 s reaction time) and high labelling yield (>99%). The I-124 was labeled successfully and in-situ labeled PEG-MNP nanocarriers were obtained. After that, I-124 and I-124-PEG-MNP were used to further preclinical evaluation by micro-PET imaging. Micro-PET images were collected at 2 h, 24 h and 48 h after intravenous injection 7.4 MBq I-124 and I-124-PEG-MNP in normal Kunming mice (n=3). The ROI target area of heart, liver and thyroid were delineated for semi-quantitative analysis. Then, in order to verify the imaging ability of I-124-PEG-MNP in solid tumor. We built human pancreatic cancer BxPC3 xenograft model (n=3), and Micro-PET scans were performed at different time points. Results showed that the labeling rate of I-124 on PEG-MNP was 99.9%. And the radiochemical purity in vitro stability of I-124-PEG-MNP in 96 h was more than 90%. Micro-PET images showed that I-124-PEG-MNP had no obvious thyroid uptake which indicated no de-marking in mice. The radio-distribution of I-124 and I-124-PEG-MNP was substantially different in liver and thyroid (P<0.001). In vivo semi-quantitative analysis showed that the radio uptakes of organs were consistent with the distribution of nanoparticles. And the PET imaging of xenograft mice showed that I-124-PEG-MNP can utilize the enhanced permeability and retention effect (EPR) to be significantly enriched at the tumor and retained in the tumor site for more than 48 h. PEG-MNP has the ability to label long half-life nuclide I-124. This research provides an experimental basis for further construction of long-circulation multimodal imaging probes.

Study on the Conditions of the Metaiodobenzylguanidine (MIGB) Labelled With131i

The study of NBS method for ~(131)Iodination labeled interferon

Radioiodinated of Gambogic Acid and Its Biodistribution in Mice

Preparation and Preliminary Molecular Imaging Study of 124I In-Situ Labeled Organic Melanin Nanoparticles

^188 Re Labeled MPEG-modified Superparamagnetic Nanogels：preparation and Preliminary Application in Mice

Direct radio-labeling of 99Tcm-IgG and its biologic distribution study

The Recent Research Progress of MIBG and Its Derivatives

Characteristics in Biodistribution and Metabolism of 131 I Labeled Immunotoxin Against Human Bladder Carcinoma in Tumor-Bearing Nude Mice

[Radiolabelling of a lung cancer-targeting small molecule polypeptide with (131)I and its radioactivity distribution in normal rabbits]

Efficacy Evaluation of 25-Year Follow-Up in 94 Cases of Malignant Pheochromocytoma with Metastases Treated by 131I- Meta-Iodo Benzyl Guanidine

Synthesis and Radioiodinelabeling of β-Amyloid Plaques Imaging Agent 3'-~(131)I-PIB

Study on Qualitative Imaging Diagnosis of Human Brain Glioma with Immuno-Radionuclide

Studies on distribution and imaging of 131I-labelled RGD peptide in mice bearing tumors

~(125)I/~(111)in Labeled Anti-EGFR Monoclonal Antibody Panitumumab:Preparation and Biodistribution Evaluation in Normal Mice

Labeling Monoclonal-Antibodies with Yttrium-90-Dota and Indium-111-Dota Chelates - A Simple and Efficient Method

131)I Labeling and Bioactivity Evaluation of a Novel RGD Dimer Targeted to Integrin Αvβ3 Receptor

Preparation and Preliminary Biological Evaluation of 99Mtc-Anmdu

Preparation, biological characterization and preliminary human imaging studies of 68Ga-DOTA-IBA

A preparation of 123I labeled side chain fatty acid BMIPP

Methods for MAG3 Conjugation and 99mtc Radiolabeling of Biomolecules

The Recent Development of the Strategy for Indirect Antibody Radiolabel with Iodine